NCT02895295: CHOICE

Evaluating a Patient-Centered Tool to Help Medicare Beneficiaries Choose Prescription Drug Plans

Completed NA Results posted Last updated 23 July 2019

What this trial tests

NA trial testing Expert Recommendation in Prescription Drug Insurance Decision Making in 1,185 participants. Completed in 20 January 2017.

Timeline

10 September 2016

Primary endpoint
20 January 2017

20 January 2017

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	1,185
Start date	10 September 2016
Primary completion	20 January 2017
Estimated completion	20 January 2017

Drugs / interventions tested

• Expert Recommendation
• Individual Analysis
• Usual Care

Conditions studied

• Prescription Drug Insurance Decision Making — all drugs for Prescription Drug Insurance Decision Making →

Sponsor

Stanford University

Who can join

Adults 66 to 85, any sex, with Prescription Drug Insurance Decision Making. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Count of Participants Whose 2017 Plan Differed From Their 2016 Plan Primary · within 50 days of the end of the open enrollment period.

Indicator of whether the self-reported plan of the participant differed before and after open enrollment and the participant reported that s/he changed plans during open enrollment.

Group	Value	95% CI
Control	85
Expert Recommendation	110
Individual Analysis	86

Decisional Conflict Primary · within 50 days of the end of the open enrollment period.

Low literacy decisional conflict scale (Linder et al., 2011), edited slightly for context of health insurance rather than treatment choice. The scale has 4 subscales (uncertainty, informed, values clarity and support) with 2 to 3 questions per subscale. Respondents can indicate "yes", "no", or "unsure" for each item. An answer of "yes" receives 0, "unsure" receives 2 and "no" receives 4 points. The sum of the responses to each question within a subscale is normalized to a scale of 25. The subscales are then summed to a total score ranging from 0 to 100 where 0 represents the lowest level of de

Group	Value	95% CI
Control	21.06	± 22.56
Expert Recommendation	20.86	± 21.99
Individual Analysis	19.56	± 22.14

Satisfaction With the Choice Process Primary · within 50 days of the end of the open enrollment period

Response to the question of, "How satisfied are you with the process of choosing a plan?" with 4 potential responses: very satisfied, somewhat satisfied, somewhat dissatisfied and very dissatisfied. The count of participants who responded "very satisfied" is reported.

Group	Value	95% CI
Control	122
Expert Recommendation	148
Individual Analysis	134

Change in Estimated Prescription Drug Spending Primary · within 50 days of the end of the open enrollment period

Change in estimated prescription drug spending is the difference in estimated spending in US dollars, including both premiums and out-of-pocket spending on prescription drugs, between the participant's 2016 and 2017 plans based on their initial drug list.

Group	Value	95% CI
Control	-178.90	± 1029.93
Expert Recommendation	-249.59	± 899.81
Individual Analysis	-197.29	± 599.38

Sponsor's own description

The objective of this study is to determine whether providing Medicare beneficiaries with a web-based patient-centered decision tool to help them choose among prescription medication coverage plans improves outcomes for patients including a greater likelihood of changing a plan, better coverage for prescribed drugs, less decisional conflict when choosing plans, and greater satisfaction with the choice process relative to current practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.